Cargando…
Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
Autophagy is a highly conserved cellular degradation process that prevents cell damage and promotes cell survival, and clinical efforts have exploited autophagy inhibition as a therapeutic strategy in cancer. Chloroquine is a well-known antimalarial agent that inhibits late-stage autophagy. We evalu...
Autores principales: | Grønningsæter, Ida Sofie, Reikvam, Håkon, Aasebø, Elise, Bartaula-Brevik, Sushma, Hernandez-Valladares, Maria, Selheim, Frode, Berven, Frode S., Tvedt, Tor Henrik, Bruserud, Øystein, Hatfield, Kimberley Joanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399694/ https://www.ncbi.nlm.nih.gov/pubmed/34442423 http://dx.doi.org/10.3390/jpm11080779 |
Ejemplares similares
-
Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020) -
The Capacity of Long-Term In Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome
por: Brenner, Annette K., et al.
Publicado: (2019) -
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
por: Nepstad, Ina, et al.
Publicado: (2019) -
Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
por: Bartaula-Brevik, Sushma, et al.
Publicado: (2023) -
Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid
por: Hernandez-Valladares, Maria, et al.
Publicado: (2021)